ArticleTranslational vision science & technology2026
Therapeutic Potential of miR-196a in Protecting Corneal Endothelial Cells From Senescence Through Mitochondrial and TGF-β Signaling Modulation.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Corneal endothelial cells (CECs) play a vital role in maintaining corneal transparency and function, with their hexagonal morphology being a hallmark of proper cellular packing and barrier integrity. This study investigates the functional role of miR-196a in regulating key cellular processes, including viability, cell cycle progression, stemness, mitochondrial function, and senescence. Methods: Human CECs were cultured and transfected with miR-196a mimics or inhibitors. Cell viability, proliferation, and cell cycle progression were assessed using the CCK-8 assay and flow cytometry. Gene expression was analyzed through real-time polymerase chain reaction and Western blotting. Mitochondrial function was evaluated using JC-1 staining and by measuring mitophagy markers. Senescence was induced using transforming growth factor β (TGF-β) and detected by senescence-associated β-galactosidase staining. Cytoskeletal changes were visualized through immunofluorescence staining. Signaling pathway activation was assessed using Western blotting and immunofluorescence. Results: miR-196a overexpression enhanced cell viability, promoted cell cycle progression, and upregulated stemness markers, while its inhibition had opposite effects. It increased mitochondrial membrane potential and suppressed mitophagy markers. miR-196a modulated autophagy, cytoskeletal dynamics, and inflammation-related pathways by regulating ROCK1, ROCK2, and PAD4. It activated prosurvival pathways (YAP, MAPK) and reduced p53 levels. Importantly, miR-196a mitigated TGF-β-induced senescence by improving mitochondrial function, suppressing autophagy, and modulating TGF-β signaling components. Conclusions: These results showed the protective role of miR-196a in maintaining cellular function and suggest its therapeutic potential for addressing aging-related diseases, fibrotic disorders, and mitochondrial dysfunction. This study underscores miR-196a as a promising target for therapies aimed at counteracting cellular senescence and promoting regenerative capacities. Translational Relevance: miR-196a may serve as a novel therapeutic target for preserving corneal endothelial function and preventing age-related degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.